Incyte CorpHere is the public summary page for Incyte Corp. Please login to see the complete information for Incyte Corp including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Incyte Corp stacks up relative to its peers. |
| Darwin Score | +1 |
| Ticker | INCY |
| Latest Price | 69.23 USD as of close on 16-Jul-2025 |
| 3 Month price range | 56.80 to 71.22 USD |
| Market Capitalisation | 13.21Bn USD |
| Country | United States of America |
| Region | North America |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. See More ... |
| Company URL | https://www.incyte.com |
| See Darwins Full Analysis for Incyte Corp |
Tell Me About
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Incyte Corp. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | +17 |
| Sentiment | News and Candle Patterns. | 0 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +1 |
| Flow | Institutional, Fund and Insider buying and selling. | -8 |
| Models | Forecast models. | -9 |
Alerts
There are 9 live alerts for Incyte Corp.
- Overbought - The 5 week RSI is +70.8. (Negative)
- Price crossing down through 5 day SMA. This alert has occurred 28 times over the last last year. The average forward returns are -0.5% over 5 days, 0.6% over 10 days, 0.4% over 15 days and 1.4% over 20 days. (Positive)
- Divergence: Px Up & 5d RSI Down last 10 days. This alert has occurred 36 times over the last last year. The average forward returns are -0.4% over 5 days, 0.3% over 10 days, 0.9% over 15 days and 3.0% over 20 days. (Negative)
- Divergence: Px Up & 30d RSI Down last 20 days. This alert has occurred 29 times over the last last year. The average forward returns are 1.9% over 5 days, 4.8% over 10 days, 3.0% over 15 days and 1.3% over 20 days. (Negative)
- Cross Over (Down): 5dma . This alert has occurred 28 times over the last last year. The average forward returns are -0.5% over 5 days, 0.6% over 10 days, 0.4% over 15 days and 1.4% over 20 days. (Negative)
- Divergence: Px Up & 15d RSI Down last 20 days. This alert has occurred 37 times over the last last year. The average forward returns are 1.2% over 5 days, 3.7% over 10 days, 2.6% over 15 days and 1.6% over 20 days. (Negative)
- Cross Over (Down): 20dma . This alert has occurred 14 times over the last last year. The average forward returns are 0.4% over 5 days, 1.7% over 10 days, 4.0% over 15 days and 5.8% over 20 days. (Negative)
- Cross Over (Up): 20dma . This alert has occurred 14 times over the last last year. The average forward returns are 0.2% over 5 days, 0.8% over 10 days, 1.6% over 15 days and 3.1% over 20 days. (Positive)
- Divergence: Px Down & OBV Up last 20 days. This alert has occurred 109 times over the last last year. The average forward returns are 0.8% over 5 days, 0.8% over 10 days, 1.2% over 15 days and 0.7% over 20 days. (Positive)
Peer Comparison
There are 22 peers of Incyte Corp.
| Asset Name | Industry Group | Asset Score |
|---|---|---|
| ACADIA Pharmaceuticals Inc (ACAD) | Biotechnology | +23 |
| Amgen Inc (AMGN) | Biotechnology | +42 |
| Arrowhead Pharmaceuticals Inc (ARWR) | Biotechnology | +9 |
| BioMarin Pharmaceutical Inc (BMRN) | Biotechnology | -5 |
| Biogen Inc (BIIB) | Biotechnology | -8 |
| Black Diamond Therapeutics Inc (BDTX) | Biotechnology | +5 |
| Dynavax Technologies Corp (DVAX) | Biotechnology | -4 |
| Exelixis Inc (EXEL) | Biotechnology | +43 |
| FibroGen Inc (FGEN) | Biotechnology | +1 |
| Gilead Sciences Inc (GILD) | Biotechnology | +11 |
| Halozyme Therapeutics Inc (HALO) | Biotechnology | +21 |
| Humacyte Inc (HUMA) | Biotechnology | -14 |
| Krystal Biotech Inc (KRYS) | Biotechnology | +3 |
| MacroGenics Inc (MGNX) | Biotechnology | -24 |
| Moderna Inc (MRNA) | Biotechnology | -7 |
| Myriad Genetics Inc (MYGN) | Biotechnology | -25 |
| Neurocrine Biosciences Inc (NBIX) | Biotechnology | +27 |
| OPKO Health Inc (OPK) | Biotechnology | -5 |
| Regeneron Pharmaceuticals Inc (REGN) | Biotechnology | -9 |
| United Therapeutics Corp (UTHR) | Biotechnology | -10 |
| Vertex Pharmaceuticals Inc (VRTX) | Biotechnology | +12 |
| Vir Biotechnology Inc (VIR) | Biotechnology | -23 |
Share 
